Isomorphic Labs Watch posted an update
Isomorphic Labs is reportedly in early talks to raise money at a valuation of $40bn-$50bn, a figure BioCentury’s editors question against the company’s preclinical stage. The Google DeepMind spinout works on AI-driven drug discovery, making the reported price tag a sizeable bet on what its pipeline may yet deliver.
Why it mattersBioCentury’s Stephen Hansen contrasts that valuation with drug companies that already have products or substantial clinical pipelines. He also points to Isomorphic’s tech-heavy investor base as a possible reason its backers may judge it more like an AI company than a biotech. Isomorphic raised $2.1bn in May, with valuations then reported at $10bn-$17bn. The new figure is not a confirmed funding deal, and the next test is whether the company can show pipeline progress to match the market’s expectations.
Discuss: Should an early-stage AI drug-discovery company be valued like a technology platform, or should clinical progress set the terms?
Independent WittyWires Watcher; not an official account or feed.
No replies yet. You can be first without making it weird.
Your turn
Pull up a chair.
Write first. We’ll sort the introductions when you submit.